$KMB

KMB Maintained by Wells Fargo -- Price Target Lowered to $105

Wells Fargo maintained an Equal-Weight rating for Kimberly-Clark (KMB) but lowered its price target from $110 to $105. GuruFocus values KMB at $123.78, suggesting a 20.4% undervaluation. The company has a GF Score of 72/100, with strengths in profitability and valuation but weaker growth prospects.

Original reporting
Published Sep 10, 2026, 7:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 4:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KMB
Bearish
medium confidence
Mentioned
$KMB
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$KMBBearishLow
01

Why it matters

Target reduction could trigger short‑term selling pressure but long‑term fundamentals remain solid.

02

Market read

Analyst target adjustments are a common catalyst for short‑term price moves in consumer staples.

03

What to watch

Potential upside from upcoming product launches and international expansion not reflected in the target.

Relevance 6/10Novelty 5/10Timing: September 10, 2026

Background

Analyst rating maintenance with a lower price target reflects cautious outlook amid sector volatility.

Company-level read

Ticker impact

$KMBBearishMedium confidence
Context

Wells Fargo lowered its price target for Kimberly-Clark to $105, indicating a more conservative valuation.

Expected impact

Potential modest downside of 2‑4% as investors adjust expectations.

Evidence & confidence

Target cuts often lead to near‑term price adjustments, especially when the new target remains above current price but signals reduced upside.

Market effects

May weigh on other consumer defensive stocks as analysts reassess valuation multiples.

Limited to U.S. consumer staples investors.

Minimal global impact.

Counterpoint

The stock remains undervalued at current price, offering a buying opportunity despite the target cut.

Key entities

  • Kimberly-Clark

    Consumer defensive manufacturer of personal care products.

  • Wells Fargo

    Equity research firm providing the rating and target.

Related articles

$KMBHighAI 9/10

Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales

Kimberly-Clark (KMB) is selling assets to address EU antitrust concerns over its $40B Kenvue acquisition, aiming for approval by September 29. The deal, expected to create a $32B revenue company, faces similar scrutiny in Australia. KMB anticipates $1.9B in annual cost synergies but may need to divest assets to secure approval.

$KMBMedAI 8/10

KMB Looks 18.8% Undervalued on GF Value™ Amid Dividend Concerns

Kimberly-Clark (KMB) shares rose 2.5% after announcing adjustments to address EU antitrust concerns over its $40B Kenvue (KVUE) acquisition. The EU decision deadline is September 29. KMB offers a 5.09% dividend yield but has a high payout ratio of 0.89, raising sustainability concerns. Its GF Value™ suggests the stock is 18.8% undervalued, with a GF Score™ of 72/100.

$KVUEMedAI 8/10

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue (KVUE) is highlighted as a strong high-yield dividend stock with a 4.68% yield and 64 years of consecutive dividend increases. Its stable of well-known brands reported Q2 revenue of $3.95B and EPS of $0.24. The company is being acquired by Kimberly-Clark (KMB), another Dividend King, which may create uncertainty about Kenvue's dividend.

$KMBHighAI 9/10

Exclusive-Kimberly-Clark prepares asset sales to win EU nod for Kenvue deal, sources say

Kimberly-Clark is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission is expected to formally raise its concerns this week. Kimberly-Clark shares rose 2.7% and Kenvue gained 2.3% on the news. The deal, announced in November, would expand Kimberly-Clark's product range to include Kenvue's brands like Listerine, Aveeno, and Neutrogena.

$KMBHighAI 9/10

Health Giants Make Big Moves and Discoveries

Kimberly-Clark negotiates EU regulators for $40B Kenvue acquisition, offering concessions. Definium Therapeutics' LSD-based drug reduced anxiety in trials. Scholar Rock's SMA drug priced at $11,659 per vial. Electra Therapeutics targets $977.6M IPO valuation. BioNTech's lung cancer treatment shows trial success.